These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 9343164)
21. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419 [TBL] [Abstract][Full Text] [Related]
22. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Enose Y; Ui M; Miyake A; Suzuki H; Uesaka H; Kuwata T; Kunisawa J; Kiyono H; Takahashi H; Miura T; Hayami M Virology; 2002 Jul; 298(2):306-16. PubMed ID: 12127792 [TBL] [Abstract][Full Text] [Related]
23. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828 [TBL] [Abstract][Full Text] [Related]
24. Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV. Sugimoto C; Watanabe S; Naruse T; Kajiwara E; Shiino T; Umano N; Ueda K; Sato H; Ohgimoto S; Hirsch V; Villinger F; Ansari AA; Kimura A; Miyazawa M; Suzuki Y; Yamamoto N; Nagai Y; Mori K PLoS One; 2010 Jul; 5(7):e11678. PubMed ID: 20652030 [TBL] [Abstract][Full Text] [Related]
25. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. Lu Y; Salvato MS; Pauza CD; Li J; Sodroski J; Manson K; Wyand M; Letvin N; Jenkins S; Touzjian N; Chutkowski C; Kushner N; LeFaile M; Payne LG; Roberts B J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):99-106. PubMed ID: 8680896 [TBL] [Abstract][Full Text] [Related]
26. Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma. Iida T; Kuwata T; Ui M; Suzuki H; Miura T; Ibuki K; Takahashi H; Yamamoto T; Imanishi J; Hayami M; Kita M Arch Virol; 2004 Apr; 149(4):743-57. PubMed ID: 15045561 [TBL] [Abstract][Full Text] [Related]
27. Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. Abel K; Rourke T; Lu D; Bost K; McChesney MB; Miller CJ J Infect Dis; 2004 Nov; 190(9):1697-705. PubMed ID: 15478078 [TBL] [Abstract][Full Text] [Related]
28. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. Nilsson C; Mäkitalo B; Thorstensson R; Norley S; Binninger-Schinzel D; Cranage M; Rud E; Biberfeld G; Putkonen P AIDS; 1998 Dec; 12(17):2261-70. PubMed ID: 9863867 [TBL] [Abstract][Full Text] [Related]
29. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge. Busch M; Abel K; Li J; Piatak M; Lifson JD; Miller CJ Vaccine; 2005 Jul; 23(31):4036-47. PubMed ID: 15963361 [TBL] [Abstract][Full Text] [Related]
31. Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time. Silverstein PS; Mackay GA; Mukherjee S; Li Z; Piatak M; Lifson JD; Narayan O; Kumar A J Virol; 2000 Nov; 74(22):10489-97. PubMed ID: 11044093 [TBL] [Abstract][Full Text] [Related]
32. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Luciw PA; Pratt-Lowe E; Shaw KE; Levy JA; Cheng-Mayer C Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7490-4. PubMed ID: 7638218 [TBL] [Abstract][Full Text] [Related]
33. Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques. Virnik K; Hockenbury M; Ni Y; Beren J; Pavlakis GN; Felber BK; Berkower I Retrovirology; 2013 Sep; 10():99. PubMed ID: 24041113 [TBL] [Abstract][Full Text] [Related]
34. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
35. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Dale CJ; Liu XS; De Rose R; Purcell DF; Anderson J; Xu Y; Leggatt GR; Frazer IH; Kent SJ Virology; 2002 Sep; 301(1):176-87. PubMed ID: 12359458 [TBL] [Abstract][Full Text] [Related]
36. Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques. Yankee TM; Sheffer D; Liu Z; Dhillon S; Jia F; Chebloune Y; Stephens EB; Narayan O Virology; 2009 Jan; 383(1):103-11. PubMed ID: 18986665 [TBL] [Abstract][Full Text] [Related]
37. Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine. Wang C; Jiang C; Gao N; Zhang K; Liu D; Wang W; Cong Z; Qin C; Ganusov VV; Ferrari G; LaBranche C; Montefiori DC; Kong W; Yu X; Gao F Viruses; 2017 Jun; 9(6):. PubMed ID: 28574482 [TBL] [Abstract][Full Text] [Related]
38. CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy. Leno M; Carter L; Venzon DJ; Romano J; Markham PD; Limbach K; Tartaglia J; Paoletti E; Benson J; Franchini G; Robert-Guroff M AIDS Res Hum Retroviruses; 1999 Mar; 15(5):461-70. PubMed ID: 10195756 [TBL] [Abstract][Full Text] [Related]
39. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease. Fultz PN; Stallworth J; Porter D; Novak M; Anderson MJ; Morrow CD Virology; 2003 Oct; 315(2):425-37. PubMed ID: 14585346 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]